Charles Swindell | CEO, Glycotest – Advancing Glycoprotein Biomarkers for Liver Disease Detection
Update: 2025-09-05
Description
In this episode of Executive Insights for Life Sciences Innovators, we speak with Charles Swindell, CEO of Glycotest, about the company’s proprietary technology that measures glycoprotein fucosylation for the detection of liver diseases. Charles shares insights on the science behind Glycotest’s platform, the challenges of bringing diagnostic innovation to market, and the future of precision liver disease detection.
Learn more at genecoda.com.
Originally recorded and streamed on YouTube Live on March 14, 2025.
Comments
In Channel





